Fate Therapeutics Shares Are Trading Lower Gaining Monday Following an Analyst Upgrade.

Fate Therapeutics Shares Are Trading Lower Gaining Monday Following an Analyst Upgrade.

BenzingaJun 26 14:35 ET

Fate Therapeutics Down Over 11%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk

Fate Therapeutics, Inc. ( FATE ) is currently at $3.30, down $0.43 or 11.42% --Would be lowest close since Dec. 20, 2023, when it closed at $3.06 --On pace for largest percent decrease since Jan. 6,

Dow JonesJun 26 13:44 ET

Intellia Therapeutics Named Edward Dulac Of Fate Therapeutics As CFO, Effective July 22, Succeeding Glenn Goddard

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dula

BenzingaJun 26 07:32 ET

Fate Therapeutics Drops To US$3.41, Yet Insiders May Have Sold Too Early

Even though Fate Therapeutics, Inc. (NASDAQ:FATE) has fallen by 12% over the past week , insiders who sold US$222k worth of stock over the past year have had less luck. Insiders might have been bette

Simply Wall StJun 19 08:45 ET

Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts

Across the recent three months, 9 analysts have shared their insights on Fate Therapeutics (NASDAQ:FATE), expressing a variety of opinions spanning from bullish to bearish.The following table encapsul

BenzingaJun 17 16:00 ET

This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag

BenzingaJun 17 09:51 ET